Reviewer's report
Title:Immunoregulatory Actions of T cell PPARgamma at the Colonic Mucosa in
Mice with Experimental IBD
Version: 1Date:6 April 2010
Reviewer: Daniel Straus
Reviewer's report:
This manuscript presents potentially interesting new results on immunoregulatory
actions of T cell PPARgamma in DSS colitis. However, there are several points
that need to be addressed:
Major compulsory revisions:
1. Figure 1: In the text the authors state that “Differences between the groups
first appeared on day 4 of the challenge, where CD4cre mice had significantly
worsened disease activity and significantly greater weight loss (Figure 1A and
1B)." Contrary to this, in Figure 1A it seems that there is no significant difference
between CD4cre and wt at any time point. On day 4, CD4cre has a “b” and wild
type has an “ab”; this means that they are not significantly different. In Figure 1B
there was a delay in weight loss in wt mice, but weight loss on day 7 was not
significantly different for the two groups.
2. Figure 2: In panels E, F and G, how many fields from how many mice were
read at each time point?
Minor essential revisions:
3. Page 15: The authors seem a little confused about clinical trials conducted
with rosiglitazone. The most recent and definitive study is their ref. 4: this was not
an open label study, it was a double-blind, placebo controlled study.
Page 6 spell “Immunophenotyping”
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Immunoregulatory Actions of T cell PPARgamma at the Colonic Mucosa in
Mice with Experimental IBD
Version: 1Date:6 April 2010
Reviewer: Daniel Straus
Reviewer's report:
This manuscript presents potentially interesting new results on immunoregulatory
actions of T cell PPARgamma in DSS colitis. However, there are several points
that need to be addressed:
Major compulsory revisions:
1. Figure 1: In the text the authors state that “Differences between the groups
first appeared on day 4 of the challenge, where CD4cre mice had significantly
worsened disease activity and significantly greater weight loss (Figure 1A and
1B)." Contrary to this, in Figure 1A it seems that there is no significant difference
between CD4cre and wt at any time point. On day 4, CD4cre has a “b” and wild
type has an “ab”; this means that they are not significantly different. In Figure 1B
there was a delay in weight loss in wt mice, but weight loss on day 7 was not
significantly different for the two groups.
2. Figure 2: In panels E, F and G, how many fields from how many mice were
read at each time point?
Minor essential revisions:
3. Page 15: The authors seem a little confused about clinical trials conducted
with rosiglitazone. The most recent and definitive study is their ref. 4: this was not
an open label study, it was a double-blind, placebo controlled study.
Page 6 spell “Immunophenotyping”
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Immunoregulatory Actions of T cell PPARgamma at the Colonic Mucosa in
Mice with Experimental IBD
Version: 1Date:6 April 2010
Reviewer: Daniel Straus
Reviewer's report:
This manuscript presents potentially interesting new results on immunoregulatory
actions of T cell PPARgamma in DSS colitis. However, there are several points
that need to be addressed:
Major compulsory revisions:
1. Figure 1: In the text the authors state that “Differences between the groups
first appeared on day 4 of the challenge, where CD4cre mice had significantly
worsened disease activity and significantly greater weight loss (Figure 1A and
1B)." Contrary to this, in Figure 1A it seems that there is no significant difference
between CD4cre and wt at any time point. On day 4, CD4cre has a “b” and wild
type has an “ab”; this means that they are not significantly different. In Figure 1B
there was a delay in weight loss in wt mice, but weight loss on day 7 was not
significantly different for the two groups.
2. Figure 2: In panels E, F and G, how many fields from how many mice were
read at each time point?
Minor essential revisions:
3. Page 15: The authors seem a little confused about clinical trials conducted
with rosiglitazone. The most recent and definitive study is their ref. 4: this was not
an open label study, it was a double-blind, placebo controlled study.
Page 6 spell “Immunophenotyping”
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests.
assistant